基因组分析公司Bionano Genomics（BNGO）今日盘中大跌6.40%，延续了该公司今年以来的颓势。此次下跌主要受到公司最新发布的第二季度财报影响，财报显示业绩低于市场预期。
根据公司公告，截至6月30日的第二季度，Bionano Genomics调整后每股亏损1.99美元，虽然较去年同期的每股亏损13.20美元有所改善，但仍未达到分析师平均预期的每股亏损2.41美元。更令投资者失望的是，公司第二季度营收仅为673万美元，同比下降13.4%，低于分析师预期的683万美元。这些数据显示公司在盈利能力和收入增长方面仍面临挑战。
值得注意的是，Bionano Genomics今年以来股价已累计下跌81.3%，反映出投资者对公司前景的担忧。尽管如此，分析师对该公司仍保持相对积极态度，目前平均评级为"买入"，12个月目标价中位数为8.00美元，较当前股价有显著上涨空间。然而，考虑到公司持续亏损的状况，市场对其短期内扭亏为盈的预期似乎并不乐观。投资者将密切关注公司未来的业绩表现和发展战略。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.